Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost

finance.yahoo.com/news/pfizer-inc-pfe-delivers-oncology-145939821.html

In This Article:
Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust five-year survival results for XTANDI (enzalutamide) combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate…

This story appeared on finance.yahoo.com, 2025-05-24 14:59:39.
The Entire Business World on a Single Page. Free to Use →